Former SignalFire Investor Raises $27.5 Million to Back AI for Drug Development
The early-stage fund will write checks of $500,000 to $1.5 million and has already backed seven startups.

TechCrunch · Proximal Ventures raises debut fund to back startups bringing AI to drug development | TechCrunchSahir Raoof, a former investor at venture firm SignalFire, has raised $27.5 million for his first solo venture fund, Proximal Ventures. The fund closed as first-time managers face one of the toughest fundraising markets in years.
Proximal will focus on young companies that use artificial intelligence to improve how drugs are developed, including tools, infrastructure, and services for pharmaceutical companies. Raoof expects such companies could provide those services for less money and in much less time.
He points to law and finance as examples where AI has been especially useful in work built around services. He thinks the same could happen in drug development support.
The firm aims to back companies at the pre-seed and seed stages, the earliest rounds of outside funding, with checks of $500,000 to $1.5 million. It has already backed seven startups.
One of them is ChronicleBio, whose co-founders include former OpenAI executive Fidji Simo. The startup applies AI to biological and medical information to study long-term illness and search for potential therapies.
Proximal's backers include venture firms SignalFire and Kleiner Perkins, along with Bertelsmann Healthcare Investments. Individual investors include Nan Li and Zavain Dar, co-founders of investment firm Dimension Capital, and Amy Abernethy, co-founder of Highlander Health and a former senior official at the Food and Drug Administration.
Abernethy first worked with Raoof at Flatiron Health, a company that organizes cancer data for research and care, where she was chief medical officer. She said his talent for forming connections and identifying bottlenecks in the industry made a lasting impression, and she expects that understanding of what the health care market needs will aid him as an investor.
Questions people ask
What are pre-seed and seed-stage startups?
Pre-seed and seed are the first rounds of outside money a startup raises, usually to build an early product and find its first customers. Checks are relatively small, often under a few million dollars, and the risk is high because the company may have little or no revenue.
What do drug-development tools and services companies do?
Drug development relies on many outside contractors for tasks such as making chemical compounds, scaling up manufacturing, running tests, and analyzing trial results. Startups in this area sell tools or services that help drugmakers do that work more quickly or cheaply, rather than developing their own drugs.
Why is fundraising tough for first-time venture managers?
Raising a first fund has been difficult because many pension funds, endowments, and other large investors have favored established firms with long track records. Higher interest rates and slower startup sales and public offerings in recent years have also made those investors more cautious about adding new managers.

